Background/Aims: Malignant mesothelioma of the tunica vaginalis testis is a rare and lethal disease. The genomic characteristics and genetic changes of tumor cells during the progression of this disease are unknown. Methods: we performed whole-genome sequencing of four successive tumor samples derived from surgery and a blood sample in a single patient. Results: All tumors were found to have significant C-to-T and T-to-C mutations, and amplification of copy number in chromosomes 1 and 12 were notified in all tumor samples. Subclone analysis revealed a parallel evolution of the tumor in this patient. We also identified some mutations in mesothelioma-associated genes such as KIF25, AHNAK, and PRDM2. Conclusions: The results showed a comprehensive genomic change in malignant mesothelioma of the tunica vaginalis testis and provide a better understanding of the clonal evolution during tumor recurrence and metastasis.
Genome Evolution Analysis of Recurrent

Introduction
The majorities of patients with cancer suffer from recurrence of the diseases and eventually die due to distant metastasis. Unfortunately, after decades of study, the processes of tumor recurrence and metastasis are still far from understood. Traditionally, local recurrence
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was thought as proliferation of residual tumor cells after treatment, and metastasis was believed to be a late-stage event. However, increasing evidences have pointed out that tumor cell dissemination can be an early-state event and local recurrence may be closely related to metastasis via homing of cancer cells [1] . These discoveries make it more difficult to unveil the mystery of tumor metastasis.
Given the intratumoral heterogeneity of tumors, it would be of great assistance to trace tumor cell expansion and migration by genome sequencing and clonal analysis [2] . Progression of cancer can be depicted under the hypothesis of tumor evolution models. However, although the branched evolution model has been widely accepted, it is under debate regarding the metastatic routes of cancer cells [3] . Both linear and parallel models are supported by evidence. Unfortunately, many evidences were acquired from carcinogeninduced or genetic engineering animal models [3] . Study of human tissue is more valuable but also tractable since the acquirement of clinical samples is extremely difficult.
Current studies of cancer genetics focus on epithelial cancer, and little knowledge has been gained regarding non-epithelial tumors. Testicular mesothelioma is a rare disease accounting for around 1% of all malignant mesotheliomas and has a grave prognosis with a median survival of less than two years [4] . The biology and genetics of this entity as well as other types of mesothelioma are largely unknown. We attempted to explore the characteristics of recurrence and metastasis of mesothelioma by assessing genetic changes on the successive tumor samples from a patient with malignant mesothelioma of the tunica vaginalis testis.
Here using whole-genome sequencing we showed the genetic characteristics of testicular malignant mesothelioma and its evolution during treatment. We retrospectively identified the recurrence and metastasis events in a single patient from successive four of his tumor samples, and also detected some mutations and genes that might important for development of this lethal disease.
Materials and Methods
Ethics approval
The tissue from a 65-year-old Chinese male was collected after radical orchiectomy in 2016. This study was performed in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects and the principles expressed in the Declaration of Helsinki, and was approved by the ethic committee of the Second Affiliated Hospital, Zhejiang University School of Medicine. Written informed consent was acquired from the patient.
Treatment history of the patient
A 65-year-old Chinese male was admitted to our hospital due to hydrocele of scrotum in both sides and tumor found in his left scrotum without asbestos exposure. All tumor markers tested were negative, and no peritoneum tumor was suggested. Radical orchiectomy was performed and malignant mesothelioma was diagnosed through conventional pathology. Local recurrence was found six years postoperatively, and the patient underwent surgery again. Unfortunately, a tumor was found in the patient's left groin, which was later confirmed as metastasis to the left inguinal lymph node by pathologists just six months later. He underwent another operation because of tumor relapse in the left groin followed by palliative radiation therapy (DT 6000cGy/30F) and systematic chemotherapy (pemetrexed 800 mg, cisplatin 40 mg d1-d3). Currently, the patient is alive without suffering significant symptoms. Formalin-fixed paraffin-embedded (FFPE) tumor samples acquired from surgeries were sectioned to 5 μm thick and hematoxylin and eosin staining of the samples confirmed the recurrence and metastasis of malignant mesothelioma in this patient.
Sample collection and DNA extraction
The FFPE tumor tissue samples were cut into 20-μm thick sections for DNA extraction. The blood sample (5 ml) was acquired from peripheral vein under full consent of the patient. DNA extraction was performed using QIAamp Whole-genome sequencing and alignment Whole-genome sequencing was performed using HiSeq X-TEN System (Illumina) by Novogene Bioinformatics Technology Co., Ltd (Novogene, Beijing, China). Effective sequence data were aligned to the UCSC hg19 of the human genome using BWA [5, 6] . Duplicate removal, local realignment, and base quality recalibration were performed using Picard, GATK [7] , and Samtools [6] , respectively. We had an average sequencing depth of 50 for tumor samples, and more than 90% of targeted bases were sequenced to a coverage of at least 20×.
Quality control
Raw reads were filtered by removing the following reads: (1) adapter reads; (2) reads with undetermined bases higher than 10% were removed; and (3) paired reads with number of low-quality bases (<5) more than 50% of total length.
Variant calling
We used MuTect to call SNVs [8] , used Strelka to call InDels [9] , and used Titan to call CNVs [10] . Each tumor sample was called against the blood sample.
Mutation validation Validation of SNVs was performed using MiSeq (Illumina).
Mutation context
Mutation spectrum analysis was performed as described before [3] , by using somatic SNVs in all tumor samples annotating with 1 of 96 possible trinucleotide-context substitutions. Each mutation context was counted and summed.
Phylogenies
Subclones in each tumor sample were identified based on somatic SNVs and copy number changes using EXPANDS analysis [11] . Phylogenetic tree was then built according to the absolute distance matrices calculated based on SNVs in these subclones and using the Kullback-Leibler divergence method.
Evaluation of predisposing genes and driver genes
We tried to identify possible driver genes in this patient by comparing mutated genes with previously reported driver genes [12] [13] [14] . SMG analysis was performed based on somatic SNVs and InDels with rates significantly higher than the background mutation rate by using MuSiC software. KEGG, Biocarta, PID, and Reactome databases were used for further pathway enrichment analysis for the identified SMGs.
Results
Mutation spectrum
To test the genome evolution during tumor recurrence and metastasis, the successive tumor samples of the patient were collected and analyzed using whole-genome sequencing (Fig. 1) . The average sequencing depths for samples CA08, CA14E, CA14L, CA15, and blood were 41.44, 46.96, 48.09, 53.37, and 34.05, respectively. Around two million singlenucleotide polymorphisms (SNPs) in the patient were detected. A total of 1328, 1628, 838, and 758 single-nucleotide variants (SNVs) were identified in samples CA08, CA14E, CA14L, and CA15, respectively. Among these SNVs, 119 of them were shared by all tumor samples ( Fig. 2A) . Since mutations in coding DNA sequence (CDS) were more probable to affect their gene products, we further focused on SNVs and insertions and deletions (InDels) in the CDS (Table 1) . The genome-wide mutation spectrum showed specific signature transversion mutations with T-to-C and C-to-T (Fig 2B and  C) . Intriguingly, later-occurring recurrent and metastatic tumors showed gradually decreased rates of C-to-T mutations. We identified three types of signatures from the 96 possible trinucleotide contexts [15] , and the relative coefficients of these signatures also had continual changes in subsequent samples (Fig. 3) .
Somatic copy number variants (CNVs)
We analyzed the CNVs of the samples, and found that all samples contained amplified CNVs in chromosomes 1 and 12. In addition, samples CA14E and CA15 also contained similar amplified CNVs in their chromosomes 6 and 11 (Fig. 4) , suggesting a special relationship between the two samples. In addition, CA15 had amplified CNVs in chromosome 18, which was not obviously observed in other samples, suggesting more complicated genetic variations in CA15 after long-term evolvement.
Evolutionary tree reveals a specific recurrence/metastatic pattern
We performed EXPANDS analysis to detect subclones in each samples based on somatic SNVs and CNVs [11] . In total, 3, 7, 6, and 5 subclones were identified in sample CA08, CA14E, CA14L and CA15, respectively. Loss of heterozygosity (LOH) was found in the secondary tumors rather than the primary tumor. Generally, more subconles were found after tumor recurrence or metastasis. In addition, changes of copy number showed a different pattern. Copy numbers of samples CA14E and CA15 were mainly 2 and 6, while copy numbers of the other two samples were more complicated (Fig. 5) . A phylogenetic tree was thus made to reveal the evolutionary relationship among the samples (Fig. 6) . It was clear that subclones from samples CA08 and CA14L were enriched and those from samples CA14E and CA15 were enriched. This result suggested that tumor cells in sample CA14L were probably originated from the primary tumor (CA08) rather than the previous recurrent lesion (CA14E), and the latest lesion (CA15) was more likely to be evolved from the recurrence of testis tumor (CA14E).
Predisposing genes and potential driver genes
Carcinogenesis of mesothelioma is frequently associated with asbestos exposure, although the patient in our study denied a history of asbestos exposure. Therefore, we (Table 2) . Unfortunately, none of these genes were previously reported as predisposing genes for mesothelioma. We also tried to identify seven candidate driver mutations, all of which were missense mutations (Table 3) .
Frequently mutated genes and pathway enrichment Significantly mutated genes (SMGs) that had significant higher mutation rates than background mutation rate were analyzed. Thirty-four genes with frequent mutations were identified (Fig. 7, Table 4 ). Noticeably, KIF25 mutation was found in all the four samples, and AHNAK mutation was found in 
Discussion
The lineage and branch models for cancer evolution have been developed and are currently under debate. On one hand, the intratumoral heterogeneity of tumor cells and environments can lead to dramatic differences in genomes of different subclones [16] . How- 6 . A Phylogenic tree showed relationship between subclones of all tumor samples. Several subclones were identified in each sample. In general, samples CA14E and CA15 were evolutionarily closer, while sample CA14L was closer to CA08 than others. Noticeably, samples CA14E and CA14L were evolutionarily far, although they were temporally close with each other. ever, the intrinsic dynamics of genome in certain types of cancer may cause some similar changes during evolution regardless of the places where malignant cells reside [3] . The shift of mutation signature may be time-dependent since less C-to-T/G-to-A mutations were detected in sample CA14L than sample CA14E, even though sample CA14L was evolutionarily closer to the primary tumor.
Although mesothelioma tends to have more C-to-A mutations than other types of cancer like lung cancer [11] , no significant change of C-to-A mutations was observed in our samples. The genomic variations of mesotheliomas originated from different organs thus can be different. Therefore, our results showed the complexity of genomic change during tumor progression, with both microenvironment-associated (extrinsic) changes and time-dependent (intrinsic) changes. It is difficult to trace tumor metastasis from the view of single tumor cells, and subclone analysis was usually used to monitor the process of tumor metastasis. Due to the limitation of sample acquirement, it is impossible to tell whether genomic change or migration of tumor cells happens first, or if they occur synonymously. In the present study, the phylogenetic tree suggested that the two metastatic lesions in left inguinal lymph node directly originated from the two tumors in the left testis. However, it is difficult to differentiate whether the lesion resected in early 2014 was recurrent from the one found in 2008, or itself was a primary tumor. Clinically, we tend to believe it was a recurrent event. However, the tumor cells had undergone extensive evolution occultly without significant proliferation during the five years. It is probable that the main subclones from samples CA08 and CA14E coexisted in the left testis and the site of left inguinal lymph node, and proliferated sequentially, resulting in the lesions found in late 2014 and 2015, respectively (Fig. 8) . Intriguingly, the total numbers of SNVs in later metastases were reduced but SMGs were increased in these samples, suggesting existence of evolution during which subclones with survival advantages were selected and enriched. Thirty frequently mutated genes with mutation types were shown. Four genes (OR2L8, KIF25, AHNAK, and LRRFIP1) were found mutated in at least three out of all four samples. Sample CA15 had the highest mutation rate in the genome but no such trend was detected in significantly mutated genes.
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From these samples, we identified some genes that may play potential roles in mesothelioma. FN1 was previously considered to be crucial in asbestos-induced malignant pleural mesothelioma (MPM) by being involved in wounding and inflammation response, ECM, and tumor cell migration [17, 18] . However, no reports of FN1 with a G1442C mutation have been published. PRDM2, a member of histone methyltransferase superfamily, is a candidate tumor suppressor and is closely related to several other critical oncogene and tumor suppressor, including RB1 and TP53 [19] [20] . Reduced expression of PRDM2 was associated with drug resistance, tumor recurrence, and tumorigenesis in some cancers [20, 21] . Consistently, a recent study using comprehensive genomic analysis recognized this gene with frequent mutations in MPM [22] . However, the mutation points in MPM (A494T and C1059G) were distinct with our study (G4399T) [22] , and whether these are loss-of-function mutations is currently unknown. In addition, non-synonymous mutations in FN1 and TSHZ2 were also detected as tumor specific mutations in MPMs, though in different points [22] . In the contrast, we failed to detect any mutations in the significantly mutated MPM-associated genes such as BAP1, NF2, TP53, SETD2, DDX3X, etc., suggesting that testicular mesothelioma harbors its own genetic characteristics different from MPM.
Moderate to strong cytoplasmic and nuclear expression of KIF25 was found in various types of cancers including testis cancer and with the exception of lymphoma. However, no report on mesothelioma was found. Particularly, KIF25 was overexpressed and essential for growth and survival of breast cancer cells, and inhibition of it by siRNA could induce nonapoptotic cell death in breast cancer by affecting lysosomal function [23, 24] . KIF25 was also recognized as a driver gene for chromatid segregation during cell mitosis, and may play roles in cancer cell proliferation [25, 26] . In this patient, we identified SNVs in KIF25 in all tumor samples, suggesting a potential role of this gene in mesothelioma. However, the function of KIF25 and the influence of these mutations remain elusive. AHNAK was previously found to be overexpressed in nearly all mesothelioma cell lines tested but not in normal mesothelial cells, and could promote migration and invasion of the malignant cells [27] . While tumor suppression roles of AHNAK have been reported in breast cancer and melanoma, the actual roles of this gene in testicular mesothelioma and the mutations detected in our study need further investigation [28] . Samples CA14L and CA15 were supposed to be originated from the primary tumor (CA08) and the early recurrent tumor (CA14E), respectively. One or more subclones from the primary tumor might move into the left inguinal lymph nodes and stay dormant or undergo latent evolution, and were rapidly proliferated as a palpable tumor in late 2014. The patient underwent postoperative chemotherapy and radiotherapy. Unfortunately, he refused to receive the adjuvant therapy until recently, which meant that the tumor evolution occurred without influence of significant stress from chemotherapeutic drugs or radiation but only surgery. Since surgery did not affect tumor cell genome directly, the results of our study revealed a relatively natural process of tumor evolution of this type of mesothelioma.
To our knowledge, this is the first study showing genetic changes of malignant mesothelioma of the tunica vaginalis testis by using high-throughput sequencing. We identified a special evolve pattern of this type of tumor, and identified certain genes that might be important for mesothelioma tumorigenesis and progression. However, some limitations exist in the current study. Firstly, only one case was studied, and it remains unclear whether these conclusions can be extended to other patients. Secondly, FFPE samples rather than fresh or frozen tissues were used for DNA extraction. Although FFPE samples qualify for the next generation sequencing, it would not be the first choice. Thirdly, the influence of the mutations on gene transcripts and the functions of these mutated proteins were not investigated. Last but not least, we did not consider the existence and evolve of circulating tumor cells, which may be responsible for the recurrence and metastases formation after operations with negative margins. Further studies are needed to validate these genetic mutations in this disease and explore the roles of mutated proteins in the development of this disease. 
